Syringes, needles, sharps containers and alcohol swabs purchased for use in novel H1N1 flu virus immunization campaign
FRANKLIN LAKES, N.J., Sept. 3 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has received a significant order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs to be used in national flu pandemic preparedness efforts.
Under the terms of the agreement, BARDA is authorized to purchase approximately $52 million of products from BD through March 2010.
"BD is pleased to be able to supply the U.S. government with syringes and other medical products for the federal vaccination campaign to protect the American people against the novel H1N1 influenza virus," said Edward J. Ludwig, Chairman and Chief Executive Officer of BD. "Due to our advance planning, we will be able to meet this large federal demand while at the same time ensuring that we are able to supply our existing customers with the regular supply for seasonal flu vaccination campaigns." BD continues to communicate with governments, vaccine companies and others worldwide to understand and plan to meet their needs to provide essential medical supplies during the flu season.
About BD BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com/. DATASOURCE: BD (Becton, Dickinson and Company) CONTACT: Colleen T. White, Corporate Communications, +1-201-847-5369, or Patricia A. Spinella, Investor Relations, +1-201-847-5453 Web Site: http://www.bd.com/
|